Abstract
Case underreporting during the COVID-19 pandemic has been a major challenge to the planning and evaluation of public health responses. Inconsistent underreporting can undermine effective risk assessment due to high uncertainty in predicted future scenarios. Underreporting rates have been particularly high among children and youth, given that asymptomatic school children were often considered a less vulnerable population. In January 2022, the Canadian province of Newfoundland and Labrador (NL) was experiencing an Omicron variant outbreak (BA.1/BA.2 subvariants) and public health officials recommended that all students returning to elementary, junior high, and high schools (∼59,452 students) complete two rapid antigen tests (RATs) to be performed three days apart. To estimate the prevalence of SARS-CoV-2, we asked parents and guardians to report the results of the RATs completed by K-12 students using an online survey, and to specify the students’ school level and if students with positive RAT results had symptoms. When comparing the survey responses with the number of cases and tests reported by the NL testing system, we found that 1 out of every 4.3 (3.1-5.3) positive households were captured by provincial case count, with 5.1% positivity estimated from the RAT results, and 1.2% positivity reported by the provincial testing system. The survey data indicate that a higher percentage of SARS-CoV-2 cases were found in elementary schools, with 62.9% of positive cases (95% CI: 44.3%, 83.0%) reported from elementary school students, and the remaining 37.1% (95% CI: 22.7%, 52.9%) reported from junior high and high school students. Asymptomatic infections were 59.8% of the positive cases, with no significant difference between asymptomatic rates in elementary schools (60.8%) or in junior high and high schools (58.1%). Given the low survey participation rate (3.5%), our results may suffer from sample selection biases, and should be interpreted with caution. Nonetheless, our estimate of the underreporting ratio is consistent with ratios calculated from serology data, and our study provides insights into infection prevalence and asymptomatic infections in school children, a currently understudied population.
We declare that
This manuscript is original and is not a violation or infringement of any existing copyright or license
The manuscript is not under consideration elsewhere
All authors meet the definition of authorship as set out by the International Committee of Medical Journal Editors (ICMJE)
Permission has been obtained from the copyright holder(s) if indicated, for the use of any third-party textual, graphic, artistic or other material
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by subgrants from the Emerging Infectious Disease Modelling Initiative groups of the Canadian Network for Infectious Disease Modelling, Mathematics for Public Health, and the One Health Modelling Network for Emerging Infectious Diseases to AH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health Research Ethics Board (HREB) at the meeting held on January 27, 2022 (Reference number: 2022.013). Participation was voluntary, and a consent was required before the survey questions were released. The consent form was approved by the Health Research Ethics Board (HREB).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
mmartignonim{at}mun.ca
zahram{at}uoguelph.ca
jcloredoosti{at}mun.ca
ahurford{at}mun.ca
Ethics approval: The study was approved by the Health Research Ethics Board (HREB) at the meeting held on January 27, 2022 (Reference number: 2022.013).
Consent to participate: Participation was voluntary, and a consent was required before the survey questions were released. The consent form was approved by the Health Research Ethics Board (HREB).
Consent for publication: The consent form and the ethic approval application specifies that results will be made public, and therefore consent for publication was provided by approval of the consent form. Consent form and signed ethic approval are attached. Availability of data and material: Data is publicly available at https://github.com/nanomaria/RAT_january
Code availability: The code used for the analysis is publicaly available at https://github.com/nanomaria/RAT_january
Funding: This study was funded by subgrants from the Emerging Infectious Disease Modelling Initiative groups of the Canadian Network for Infectious Disease Modelling, Mathematics for Public Health, and the One Health Modelling Network for Emerging Infectious Diseases to AH.
Conflict of interest: None to declare.
Underreporting table is revised, and the underreporting ratio for BC is now 17.2, for PEI is 1.0, and for NL is 2.3.
Data Availability
All data produced in the present work are contained in the manuscript
